You are here

Phase III Trial of Autologous MSCs for Perianal Fistula

A recent STEM CELLS Translational Medicine article from researchers led by Mariano García‐Arranz (Universidad Autónoma de Madrid, Spain) provides evidence of the safety of autologous adipose-derived mesenchymal stem cell (MSC) therapy for complex perianal fistula in a phase III multicenter, randomized, single‐blind clinical trial. Furthermore, the authors suggest that this approach also provides an advantage over a good surgical protocol at two years after treatment; however, following this time, results stay similar to those shown with allogenic MSCs in previous clinical trials.